The technology for this influenza vaccine is believed to be the first human drug in the world to be completely designed by artificial intelligence.
Researchers are working to develop a universal influenza vaccine to protect against all strains of the virus.
Researchers described a new cell line that enables better growth of H3N2 for vaccine use. The virus is also less likely to mutate during production using this cell line.
If the influenza virus was an ice cream cone, then the annual vaccine teaches the immune system to recognize just the scoop – requiring the vaccine to change annually as the virus changes. A new approach has been studied that teaches the body to recognize the cone portion of the virus – which stays the same year-to-year unlike the icre cream portion.
Immune cells which could fight all kinds of influenza virus have been discovered by scientists, raising hope for a universal vaccine which does not need to be update annually.
The H5N1 avian influenza antigen and adjuvant maintained their functional integrity in the National Pre-Pandemic Influenza Vaccine Stockpile (NPIVS), according to testing by the US Biomedical Advanced Research and Development Authority (BARDA).
Vaccines are one of the great success stories of modern medicine. The flu vaccine, however, is a different story. Its effectiveness varies from patient to patient, from population to population, and from year to year.
Health experts should only replenish flu vaccines in areas that need them, researchers argue in a new paper.
As part of our nation’s overall pandemic preparedness strategy, the US Department of Health and Human Services (HHS) set a preparedness goal of establishing and maintaining a stockpile of bulk vaccine antigen and adjuvants for influenza viruses with pandemic potential to vaccinate 26 million people immediately after a pandemic is declared.
The US Biomedical Advanced Research and Development Authority (BARDA) conducted a randomized, double-blinded Phase 2 clinical study with the oldest stockpiled influenza A(H5N1) antigen, stored over the previous 10–12 years administered with or without MF59® adjuvant, stored over the previous 2–7 years at the time of vaccination.